SEC filings and other documents

ADG126 demonstrates strong efficacy and safety in MSS CRC and HCC, backed by strategic partnerships.

ADG126 demonstrates promising efficacy and safety in MSS-CRC, with robust funding and strategic partnerships.

ADG126 shows strong efficacy and safety in MSS CRC, backed by strategic partnerships and innovation.

ADG126 plus pembrolizumab delivers strong efficacy and safety in late-line MSS CRC, backed by key partnerships.

ADG126 shows promising efficacy and safety in MSS CRC, with pipeline and partnership expansion underway.

ADG126 demonstrates strong efficacy and safety in late-line MSS-CRC, with key data updates expected.

Muzastotug achieved 29% ORR in MSS CRC, revenue soared, and cash runway extends into 2028.

AI-driven masked antibody ADG126 achieves 29% response in MSS-CRC, backed by SNOWPEA funding.

Strong clinical progress and expanded Sanofi partnership position the pipeline for key 2026 milestones.

Strong clinical and financial progress, with Sanofi investment extending cash runway into 2027.

ADG126 delivers strong efficacy and safety, with major regulatory and clinical updates expected soon.

SAFEbody anti-CTLA-4 shows strong efficacy and safety in MSS CRC, with pipeline innovation ongoing.

Epitope-driven CTLA-4 therapy shows promise in MSS CRC with flexible dosing and regulatory momentum.

ADG126 achieved 33% ORR in MSS CRC; cash runway extends into late 2026.

Clinical data show potent, safe antibody therapies with broad expansion and partnership plans.

Lead program ADG126 shows strong efficacy and safety, with major data updates and expansion ahead.

SAFEbody technology enables high-dose anti-CTLA-4 therapy with strong efficacy and safety in MSS CRC.

Net loss widened to $17M as Adagene advances ADG126 and maintains a $95.7M cash runway.